Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study

Oncology
E EndlicherF Kullmann

Abstract

The aim of the present study was to evaluate the 6-month survival rate of patients with inoperable or metastatic pancreatic cancer treated with irinotecan and gemcitabine plus 5-fluorouracil. Secondary efficacy end points included response rate, time to progression (TTP), overall survival (OS) and toxicity. 30 patients with histologically proven pancreatic carcinoma and at least one bidimensionally measurable lesion were enrolled. Of the patients, 83% had metastatic and 17% locally advanced disease. One cycle, lasting 21 days, comprised treatment on days 1 and 8 consisting of 75 mg/m(2) irinotecan i.v. for 90 min, 1,000 mg/m(2) gemcitabine i.v. for 30 min and 2,000 mg/m(2) fluorouracil (5-FU) for 24 h. A total of six cycles was planned for each patient. 28 patients competed at least one treatment cycle and were therefore assessable for efficacy, and 75% of them achieved the primary end point of the study (survival after 6 months). One-year survival was 25%. Stabilization (partial response and stable disease) was observed in 35.7% (10/28) and partial remission in 7.1% (2/28). The objective response rate was 7.1% (2/28) after completion of the six cycles. Median TTP was 3.4 months (1.2-11.5), and median OS was 8.3 months (2.1-36....Continue Reading

References

Jan 1, 1981·Cancer·A B MillerA Winkler
Jun 1, 1994·The British Journal of Surgery·K R PalmerR C Leonard
Aug 1, 1996·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusC Svensson
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caio Max S Rocha LimaMark R Green
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Dec 5, 2003·Alimentary Pharmacology & Therapeutics·S ShoreJ P Neoptolemos
Feb 21, 2004·CA: a Cancer Journal for Clinicians·Ahmedin JemalUNKNOWN American Cancer Society
Apr 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemD Von Hoff
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caio M Rocha LimaLangdon L Miller
Apr 28, 2006·Journal of Gastroenterology and Hepatology·Her-Shyong ShiahLi-Tzong Chen
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ghassan K Abou-AlfaEileen M O'Reilly

❮ Previous
Next ❯

Citations

Sep 13, 2012·World Journal of Gastroenterology : WJG·Cindy NeuzilletPascal Hammel
Feb 5, 2014·Nature Reviews. Urology·Gil Redelman-SidiBernard H Bochner
Mar 24, 2009·Cancer Science·Takuya EgamiMasao Tanaka
Jan 10, 2012·Cancer Treatment Reviews·Volker HeinemannStefan Boeck
Aug 19, 2009·Physics in Medicine and Biology·Issam El NaqaJoseph O Deasy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.